WAM
ADAP

Worth Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Worth Asset Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-600
Closed -$555 – 98
2023
Q2 		$555 Hold
600
– – ﹤0.01% 431
2023
Q1 		$654 Hold
600
– – ﹤0.01% 447
2022
Q4 		$876 Hold
600
– – ﹤0.01% 430
2022
Q3 		$1K Hold
600
– – ﹤0.01% 418
2022
Q2 		$1K Hold
600
– – ﹤0.01% 487
2022
Q1 		$1K Buy
+600
New +$1.62K ﹤0.01% 493

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Worth Asset Management's ADAP Position: Q3 2023 in Review

Worth Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q3 2023, closing a stake of 600 shares — an estimated $555 sold.

Worth Asset Management first reported a position in ADAP in Q1 2022 and held it in 6 quarters. The position peaked at $1K in Q3 2022. 79 funds tracked by Wall St. Rank hold ADAP as of Q3 2023.

  • Worth Asset Management reported no remaining Adaptimmune Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Worth Asset Management sold 600 Adaptimmune Therapeutics shares in Q3 2023, an estimated $555.
  • Worth Asset Management first reported a position in Adaptimmune Therapeutics in Q1 2022 and held it in 6 quarters.
  • Worth Asset Management's Adaptimmune Therapeutics position peaked at $1K in Q3 2022.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2023.

Based on Worth Asset Management's 13F filing for Q3 2023, filed 11 Oct 2023.